JUNIPER-NETWORKS
15.3.2022 13:49:04 CET | Business Wire | Press release
Juniper Networks , (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Raiffeisen Informatik (R-IT), a provider of comprehensive IT-services for financial service and insurance providers, has deployed Juniper Apstra data center solutions to modernize and automate its network infrastructure to provide exceptional services for its customers.
R-IT works consistently and emphatically to provide high-quality services and fail-safe infrastructures to its customers 24/7. R-IT’s long standing customers rely on the provider’s consistent and innovative solutions that significantly increase their flexibility as well as R-IT’s added value, from lending business and receivables management through securities settlement, to data management and digitalized accounting.
Juniper Apstra, the company’s data center solution for automation, will simplify planning, design and operations for R-IT’s network teams, reducing configuration errors for a more predictable data center network while maximizing both reliability and speed to create a better user experience.
News Highlights:
- R-IT can simplify and automate its operations from design to deployment (Day 0 and 1) through everyday operations and assurance with the turnkey Apstra System.
- Apstra usesroot-cause analysis to reduce the duration of network issues and shorten maintenance time with maintenance-mode capabilities. With Apstra, R-IT can dramatically reduce the time needed to deliver new network services, achieving faster time to deployment and time to resolution.
- With automated, flexible and simplified operations, R-IT can push out new application updates and services with minimal downtime for smooth, consistent user experiences.
- By automating the network lifecycle, IT resources can be used more efficiently, freeing up the company’s talented IT staff for strategic work. Pressure on hiring infrastructure and operations staff is expected to be relieved.
- With its open, flexible architecture, Apstra enables R-IT to deploy and operate multivendor networks with the ease and simplicity of a single-vendor network.
- In R-IT’s data centers, Juniper QFX Series Switches provide a flexible network fabric with industry-leading throughput and scalability, an extensive routing stack, the open programmability of the Junos® OS and a broad set of EVPN-VXLAN and IP fabric capabilities.
Supporting quotes:
“Our deep industry knowledge and strong foundation help ensure that our customers receive the best IT service at the highest levels of security, performance and availability, so they can concentrate on their core processes. Juniper Apstra provides an automated network platform that allows us to serve our customers with greater business agility.”
- Michael Linhart, CEO, Raiffeisen Informatik
“Financial institutions are looking for operational services that are reliable, resilient and agile. R-IT is providing critical services to its customers 24/7, and Juniper supports that with our objective to fully automate changes and assure continuous operation. With intent-based networking automation to help modernize and automate R-IT’s complete data center, Apstra increased reliability without more headcounts.”
- Mike Bushong, Vice President, Data Center Product Management, Juniper Networks
Additional resources:
- Success Story: R-IT
- Follow Juniper Networks online: Facebook | Twitter | LinkedIn
- Juniper Blogs and Community: J-Net
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net ) or connect with Juniper on Twitter , LinkedIn and Facebook .
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
category-enterprise
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005126/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom